The Cambridge-based biotech was co-founded by Atlas Ventures and CEO Alex Lugovsky to develop agonist antibodies for rare diseases, with a lead program in hereditary hemorrhagic telangiectasia.
The Cambridge-based biotech was co-founded by Atlas Ventures and CEO Alex Lugovsky to develop agonist antibodies for rare diseases, with a lead program in hereditary hemorrhagic telangiectasia.